BD Pharmingen- FITC Rat Anti-Human IL-4_BD Pharmingen
参考图片
Expression of IL-4 by stimulated human peripheral blood mononuclear cells (PBMC). Human PBMC were stimulated with soluble anti-human CD3 antibody (1 µg/ml final concentration; Cat. No. 555329), recombinant human IL-2 (10 ng/ml final concentration; Cat. No. 554603) and recombinant human IL-4 (10 ng/ml final concentration; Cat. No. 554605) for 2 days. The cells were subsequently cultured in medium containing recombinant human IL-2 and recombinant human IL-4 for 3 days. Finally, the cells were harvested and stimulated for 6 hours with PMA (Sigma) and calcium ionophore A23187 (Sigma) in the presence of GolgiStop™ (2µM final concentration; Cat. No. 554724). The cells were harvested, stained with PE-Cy5™-anti CD4 (.25 µg final concentration; Cat. No. 555348), fixed, permeabilized, and subsequently stained with 0.12 µg of FITC-rat anti-human IL-4 antibody (FITC-MP4-25D2, Cat. No. 554484) by using the BD Pharmingen staining protocol (left panel). To demonstrate specificity of staining, the binding of FITC-MP4-25D2 antibody was blocked by preincubation of the fixed/permeabilized cells with unlabelled MP4-25D2 antibody (2.5 µg, Cat. No. 554482; right panel) prior to staining. The quadrant markers for the bivariate dot plot were set based on the autofluorescence controls and verified using unlabelled antibody blocking controls.
本文来自投稿,不代表本人立场,如若转载,请注明出处:http://www.iamyjet.com/kangti/9619.html